Free Newsletter
Merck’s rotavirus vaccine makes big impact
A new report by the CDC concludes that Merck's new rotavirus vaccine has made a major impact on the disease in the last two years. RotaTeq, designed to prevent diarrhea and vomiting in children, has pushed the start of the rotavirus season back by three months and reduced the severity of the season by half. Incidences of the disease plunged soon after the vaccine was approved and swiftly hit their lowest level since figures were first gathered 15 years ago. Rotavirus is highly contagious and has been blamed for 272,000 ER visits in the U.S. each year.
- read the report in the Philadelphia Inquirer
Related Articles:
FDA approves Merck's rotavirus vaccine
Vaccine may be linked to bowel problems in children
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A; Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
More Research Reports >>
